Follow us for updates
© 2021
Read the Story →

Antidepressant Reduced COVID-19 Risk of Hospitalization: Study

Addressing a grossly uneven vaccine rollout.
by Agence France Presse
Just now
Photo/s: shutterstock

PARIS -- Treating high-risk COVID-19 patients with the antidepressant fluvoxamine may reduce the risk of prolonged hospitalization by up to a third, a large-scale study showed Thursday.

Authors said the research could help boost low-cost protection against severe sickness or death in countries that have yet to receive adequate vaccine doses during a grossly uneven rollout.

Fluvoxamine is traditionally used to treat mental health conditions such as depression and obsessive-compulsive disorders and was selected for trial due to its anti-inflammatory properties.

Many problems stemming from COVID-19 are caused by swelling as the immune system overreacts to the infection. 


Greta Thunberg Rues 'Tragedy' of Vaccine Inequality

UN Chief Scolds Rich Nations for 'Stupid, Immoral' Vaccine Hoarding

WHO is Mass-Testing Three Potential COVID Treatments

Writing in the journal The Lancet Public Health, researchers from North and South America, described results in nearly 1,500 COVID-19 outpatients in Brazil.

Of the 741 people that received fluvoxamine, 79 -- just over 10% -- had an extended stay in hospital. 

Continue reading below ↓

Of the 756 who received a placebo, 119 (15.7%) were hospitalized. 

Authors said that administering fluvoxamine resulted in a relative reduction in hospitalisations of 32%.

"COVID-19 still poses a risk to individuals in countries with low resources and limited access to vaccinations," said Edward Mills of McMaster University, co-principal investigator on the trial. 

"Identifying inexpensive, widely available, and effective therapies against COVID-19 is therefore of great importance, and repurposing existing medications that are widely available and have well-understood safety profiles is of particular interest."

Although reducing deaths was not an intended area of focus, the study also found that 12 patients in the placebo group ended up dying, while just one from the fluvoxamine group succumbed to the virus. 

Continue reading below ↓
Recommended Videos

The authors stressed that further evaluation is needed as fluvoxamine isn't on the World Health Organization's list of essential medicines and can be addictive.

"Given fluvoxamine's safety, tolerability, ease of use, low cost, and widespread availability, these findings may have an important influence on national and international guidelines on clinical management of COVID-19," said Gilmar Reis, study co-lead, based in Belo Horizonte, Brazil.

Continue reading below ↓


Booster Shot vs Third Dose COVID Vaccine: What's the Difference?

COVID-somnia Keeping You Awake? Here's How to Get a Good Night Sleep

Imagination Can Help Beat COVID Blues, Here's How Cognitive Reappraisal Works

How COVID Smell Loss Can Have Profound Effects on Your Life

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.